zidesamtinib

London, United Kingdom, September 13, 2026 GSK has announced positive registrational data from the Phase I/II ARROS-1 trial supporting...

LONDON, United Kingdom, July 23, 2026 GSK plc has announced that the U.S. Food and Drug Administration (FDA) has...

Cambridge, Massachusetts, USA, April 21, 2026 In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the...

CAMBRIDGE, Mass., April 17, 2026 Nuvalent, Inc. has reported compelling clinical and preclinical data for its investigational drug zidesamtinib,...

Cambridge, Massachusetts — November 19, 2025 — Nuvalent, Inc. announced that the U.S. Food and Drug Administration (FDA) has...